Compare Stocks: GILD, CHLL, HELD, and BRNS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$0.71 +7.0%	$0.62	$0.51 ▼ $1.83	$26.96M	-0.39	34,839 shs	66,392 shs
GILD Gilead Sciences	$148.09 -0.5%	$133.31	$108.46 ▼ $157.29	$184.47B	0.32	6.68 million shs	5.26 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	+9.65%	+6.29%	+9.47%	-5.83%	-44.85%
GILD Gilead Sciences	+1.38%	+3.72%	+15.05%	+11.28%	+30.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$0.71 +7.0%	$0.62	$0.51 ▼ $1.83	$26.96M	-0.39	34,839 shs	66,392 shs
GILD Gilead Sciences	$148.09 -0.5%	$133.31	$108.46 ▼ $157.29	$184.47B	0.32	6.68 million shs	5.26 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	+9.65%	+6.29%	+9.47%	-5.83%	-44.85%
GILD Gilead Sciences	+1.38%	+3.72%	+15.05%	+11.28%	+30.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	466.25% Upside
GILD Gilead Sciences	2.83	Moderate Buy	$158.04	6.72% Upside

Current Analyst Ratings Breakdown

Latest GILD, CHLL, HELD, and BRNS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	GILD Gilead Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C-)
8/5/2026	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$120.00 ➝ $123.00
8/5/2026	GILD Gilead Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$155.00
8/5/2026	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$170.00
7/29/2026	GILD Gilead Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/29/2026	GILD Gilead Sciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$155.00 ➝ $145.00
7/27/2026	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$166.00 ➝ $165.00
7/21/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	GILD Gilead Sciences	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$146.00 ➝ $127.00
7/8/2026	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$168.00 ➝ $166.00

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	1.93	N/A	N/A	$1.40 per share	0.50
GILD Gilead Sciences	$29.44B	6.24	$10.42 per share	14.21	$9.47 per share	15.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/5/2026 (Estimated)
GILD Gilead Sciences	$8.51B	-$2.67	N/A	15.27	N/A	-10.64%	-2.11%	-0.75%	10/29/2026 (Estimated)

Latest GILD, CHLL, HELD, and BRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A
8/3/2026	Q2 2026	GILD Gilead Sciences	-$7.25	-$6.75	+$0.50	-$8.45	$7.40 billion	$7.80 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.28	2.21%	+3.04%	N/A	10 Years

Latest GILD, CHLL, HELD, and BRNS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	GILD Gilead Sciences	quarterly	$0.82	2.43%	9/15/2026	9/15/2026	9/29/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
GILD Gilead Sciences	2.03	1.27	1.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
GILD Gilead Sciences	83.67%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	8.50%
GILD Gilead Sciences	0.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable

GILD, CHLL, HELD, and BRNS Headlines

Recent News About These Companies

Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences

August 26 at 6:02 PM | finance.yahoo.com

Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences

August 26 at 4:05 PM | businesswire.com

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting

August 26 at 1:01 PM | fool.com

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting

August 26 at 9:51 AM | fool.com

Man Group plc Invests $156.06 Million in Gilead Sciences, Inc. $GILD

August 26 at 6:31 AM | marketbeat.com

Roberts Glore & Co. Inc. IL Makes New $1.25 Million Investment in Gilead Sciences, Inc. $GILD

August 26 at 6:16 AM | marketbeat.com

Jupiter Topco LLC Buys New Stake in Gilead Sciences, Inc. $GILD

August 26 at 6:15 AM | marketbeat.com

Quantbot Technologies LP Makes New Investment in Gilead Sciences, Inc. $GILD

August 26 at 5:11 AM | marketbeat.com

2,455,920 Shares in Gilead Sciences, Inc. $GILD Acquired by Canada Pension Plan Investment Board

August 26 at 4:16 AM | marketbeat.com

527,542 Shares in Gilead Sciences, Inc. $GILD Acquired by Castleark Management LLC

August 26 at 4:15 AM | marketbeat.com

Ancora Advisors LLC Invests $15.35 Million in Gilead Sciences, Inc. $GILD

August 26 at 3:21 AM | marketbeat.com

EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC

August 25 at 3:16 PM | zacks.com

Best Medical Stocks Worth Watching - August 25th

August 25 at 2:01 PM | marketbeat.com

10,421,131 Shares in Gilead Sciences, Inc. $GILD Purchased by Legal & General Group Plc

August 25 at 6:24 AM | marketbeat.com

The Manufacturers Life Insurance Company Takes Position in Gilead Sciences, Inc. $GILD

August 25 at 6:24 AM | marketbeat.com

Van Hulzen Asset Management LLC Acquires New Shares in Gilead Sciences, Inc. $GILD

August 25 at 6:08 AM | marketbeat.com

L2 Asset Management LLC Takes $8.15 Million Position in Gilead Sciences, Inc. $GILD

August 25 at 6:07 AM | marketbeat.com

Manning & Napier Advisors LLC Invests $12.99 Million in Gilead Sciences, Inc. $GILD

August 25 at 6:00 AM | marketbeat.com

Ieq Capital LLC Buys Shares of 33,739 Gilead Sciences, Inc. $GILD

August 25 at 5:12 AM | marketbeat.com

Dearborn Partners LLC Purchases Shares of 69,875 Gilead Sciences, Inc. $GILD

August 25 at 4:31 AM | marketbeat.com

EC expands role of Gilead’s Trodelvy

August 24 at 5:38 PM | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GILD, CHLL, HELD, and BRNS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$0.71 +0.05 (+7.03%)

As of 03:59 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Gilead Sciences NASDAQ:GILD

$148.09 -0.68 (-0.46%)

As of 04:00 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GILD, CHLL, HELD, and BRNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GILD, CHLL, HELD, and BRNS Earnings

Compare Dividends

Latest GILD, CHLL, HELD, and BRNS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GILD, CHLL, HELD, and BRNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GILD, CHLL, HELD, and BRNS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

Gilead Sciences NASDAQ:GILD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GILD, CHLL, HELD, and BRNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GILD, CHLL, HELD, and BRNS Earnings

Compare Dividends

Latest GILD, CHLL, HELD, and BRNS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GILD, CHLL, HELD, and BRNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GILD, CHLL, HELD, and BRNS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

Gilead Sciences NASDAQ:GILD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools